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Abstract
Adenovirus  (AdV)  infection  in  the  course  of  allogeneic  stem  cell  transplantation  (SCT)  is 
associated  with  high  transplant-related  morbidity  and  mortality.  Disseminated  AdV  disease  is 
lethal in most instances. Early detection of AdV infection and identification of patients carrying a 
high risk of disseminated disease therefore remain a major challenge. In view of the large number 
of existing AdV types, we have established real-time PCR assays permitting sensitive detection 
and quantification of all 51 currently known human AdV serotypes. In a series of 132 consecutive 
pediatric SCT patients, more than 5000 samples derived from PB, stool, urine, and throat were 
screened for adenovirus infection by PCR during the post-transplant period. Thirty six patients 
(27%) tested positive by PCR, revealing AdV types of the subgenera A, B, C, D and F. Except for 
enteritis in some patients with AdV positivity in stool, detection of the virus at sites other than PB 
was not associated with clinical signs of virus disease, and transplant-related mortality was not 
significantly  different  from  AdV  negative  patients.  By  contrast,  82%  of  patients  who  had 
detectable AdV in PB died from infectious complications (p<0.001). Monitoring of PB specimens 
by real-time PCR permitted early diagnosis of invasive AdV infection in all instances. In patients 
who developed disseminated AdV disease, detection of the virus in PB preceded onset of clinical 
symptoms by a median of over three weeks. The observation of AdV in peripheral blood may 
therefore serve as a basis for early initiation of preemptive antiviral treatment.
Lion@ccri.univie.ac.at
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Introduction
Adenoviruses are pathogens causing serious infections in allogeneic bone marrow transplant (allo-
BMT) recipients 
1-3. To date, 51 different human AdV serotypes have been identified 
4; 5. They are 
divided into six major subgroups (subgenera or species A-F) on the basis of their oncogenic, 
hemagglutinating,  morphological,  and  DNA  sequence  properties 
6-8.  In  immunosuppressed 
patients, any adenovirus species may cause life-threatening infections 
2;  3;  8;  9. In most clinical 
situations involving adenovirus infection, species identification of an AdV isolate is as informative 
as a finer identification by serotype 
6.
In different studies, adenoviruses have been found to infect up to 20% of patients receiving allo-
BMT,  with  a  particularly  high  incidence  of  infection  and  virus  disease  in  children 
8;  10;  11. 
Infections can be asymptomatic or cause localized disease such as enteritis, upper respiratory tract 
infection or cystitis 
12. However, AdV infections in allo-BMT recipients tend to become invasive, 
and disseminated disease is associated with very high mortality 
8;10; 11 12 - 17.
Earlier diagnostic approaches to AdV detection relied mainly on serological tests and cell culture 
18-23. In immunocompromised patients, however, the use of serological tests is limited due to the 
impaired immune response, and evaluation of positive cultures is a relatively slow method 
24. The 
recent  introduction  of  PCR-based  assays  has  opened  new  ways  to  rapid,  specific  and  highly 
sensitive AdV detection 
4; 12-15; 17; 25.
In view of the fact that many of the published diagnostic approaches do not effectively cover all 
AdV  types,  we  have  established  species-specific  real-time  PCR  assays  permitting  reliable 
detection and quantification of all 51 currently known human AdV serotypes. In the current study 
in  pediatric  patients  after  allogeneic  stem  cell  transplantation,  we  have  addressed  the  clinical 
significance of molecular AdV detection, and investigated the potential of serial real-time PCR 
analysis to facilitate diagnosis of invasive infection early in its pre-clinical stage. 
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Patients and Methods
Patients
All pediatric patients who underwent allogeneic stem cell transplantation (allo-SCT) at St.Anna 
Children´s Hospital, Vienna, Austria, between June 1996 and May 2002 were included in the 
study (n=132). Written informed consent was obtained from each patient and/or the parents, and 
the transplant protocol has been approved by the institutional review board of St. Anna Children´s 
Hospital. Patient characteristics and transplant modalities are summarized in Tab.1. Ex vivo T-cell 
depletion  by  CD34+  selection  was  performed  in  case  of  1-AG  mismatched  unrelated  or 
haploidentical  family  donors.  Patients  with  severe  combined  immunodeficiency,  patients  with 
severe aplastic anemia and patients with mismatched or unrelated donors received ATG from day 
-3 to -1. GvHD prophylaxis consisted of cyclosporine A and, in recipients of non-T-cell depleted 
grafts from unrelated donors, of an additional short MTX course. All patients were nursed in 
laminar air flow units. Antiviral prophylaxis consisted of acyclovir 30 mg/kg/day i.v. from day -7 
until day + 28 and immunoglobulin substitution every three weeks, until day +100. 
Patients  with  a  positive  PCR  test  in  peripheral  blood  for  CMV  or  AdV  were  eligible  for 
preemptive  antiviral  treatment,  regardless  of  the  viral  load.  Treatment  was  initiated  upon 
availability  of  PCR  results,  generally  within  48-72  hours  after  sampling.  Patients  with  CMV-
DNAemia  received  primary  preemptive  therapy  with  gancyclovir  and,  in  case  of  persistent 
DNAemia, secondary preemptive treatment with foscarnet, until two consecutive negative results 
were obtained. Patients with adenovirus-DNAemia transplanted between October 1998 and May 
2002 (n = 7) received preemptive treatment with cidofovir (5mg/kg/week; according to a protocol 
requiring continuation of treatment until attainment of two negative PCR results). 
Sample collection
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Whenever possible, patients were tested prior to transplantation, and prospective virus screening 
in peripheral blood (PB), stool, urine and throat for CMV, EBV, AdV, HHV6, and HHV7 was 
performed at three- to seven-day intervals until day +28. Subsequently, the intervals in patients 
who tested negative were extended to one to two weeks, until day +100 post-transplant. In patients 
who tested positive for any virus until day + 28, the screening was continued at three- to seven-
day intervals, until two consecutive negative results were obtained. After day +100, tests were 
carried out only in case of clinically suspected viral infection. More than 5000 samples derived 
from the sites indicated above, and occasionally from cerebrospinal fluid, organ biopsies, and 
bone  marrow,  were  screened  by  PCR-based  DNA  analysis.  The  average  number  of  samples 
investigated in each patient was 50 (range: 11-75). 
Isolation of viral DNA
DNA extraction from largely cell-free liquids except urine, and from peripheral blood leukocytes 
for  detection  of  intracellular  virus  particles  was  performed  using  QIAamp  DNA  Mini  Kit. 
Isolation of virus DNA from urine was done using the QIAamp Viral RNA Mini Kit, and from 
stool by the QIAamp DNA Stool Mini Kit (QIAGEN GmbH, Hilden, Germany) according to the 
manufacturer´s recommendations.
Quantitative PCR analysis of AdV 
Six  different  primer/probe  systems  were  designed  on  the  basis  of  the  available  AdV  DNA 
sequence  information  (NCBI  Database)  to  permit  detection  of  the  individual  AdV  species 
(subgenera) A-F. The AdV DNA sequences targeted by the primer/probe systems were derived 
from the hexon, and VA RNA genes. The characteristics of the primers/probes used are indicated 
in Tab.2. Reference strains of all 51 human adenovirus serotypes (kindly provided by H. Niesters, 
Dept Virology, University of Rotterdam, The Netherlands) were used as positive controls for the 
establishment of AdV-specific real-time PCR assays. Each of the six primer/probe systems were 
For personal use only. on November 3, 2014.  by guest    www.bloodjournal.org From 6
shown to permit sensitive and specific detection of all AdV serotypes belonging to the respective 
species. The only cross reactivity observed, involved the detection system for AdV species B 
which recognized also species E (including only serotype 4). By contrast, the detection system for 
species E detected exclusively this genotype under the conditions used. 
PCR reactions were set up in a total volume of 25 µl including 6 µl template DNA, and 12.5 µl 
TaqMan Universal Master Mix. The concentration of primers and FAM-labelled probe for each 
detection system are displayed in Tab.2. Amplifications were carried out using the ABI Prism 
7700 or 7900 Sequence Detectors (Applied Biosystems, Foster City, Ca, USA) for a total of 50 
cycles. After an initial denaturation step for 10 min at 95°C, each cycle consisted of denaturation 
for 15 sec at 95°C, and annealing and primer extension for 60 sec at 60°C. 
Strict precautions were undertaken to prevent contamination of PCR reactions with exogenous 
products as described 
26. A dUTP glycosylase step was performed prior to each PCR reaction. 
Each DNA sample was analyzed in duplicate, and multiple negative controls were included in 
each assay. 
For  quantitative  analysis  of  virus  load,  real-time  TaqMan  PCR  was  performed  using  the 
equipment indicated above. External standard curves for each AdV species were established by 
making  serial  dilutions  of  quantified  virus  preparations  derived  from  reference  strains.  For 
assessment of virus copies per cell, a single copy gene (beta2 microglobulin) was quantified in 
parallel  by  real-time  PCR 
27.  When  investigating  cell-free  liquids,  quantitative  results  were 
expressed as the number of virus copies per ml. In stool samples, the virus copies were calculated 
per gram material, and intracellular virus copies were indicated per 10
6 cells.
The sensitivity of the PCR assays permitted reliable detection of 2x10
2 virus particles per ml of the 
medium investigated. For reproducible quantification of virus load, however, the presence of >10
3
particles per ml was necessary. When analyzing cell material, sensitivity of the assays permitted 
detection and quantification of virus copies at a level of 10 particles per 10
6 cells. 
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Statistical analysis
The risk factors for AdV infection analyzed in the univariate analysis included T cell depletion in-
and  ex-vivo,  underlying  disease,  type  of  donor,  graft  versus  host  disease  of  all  grades,  and 
presence of other virus infections. Differences between patient groups including 1) AdV negative 
patients, 2) patients positive for AdV at one or two sites, but negative in PB, and 3) patients 
positive  for  AdV  in  PB  were  analyzed  using  Chi-Square  Test.  For  analysis  of  small  cohorts, 
Fisher´s Exact Test was employed. The association between AdV infection and graft versus host 
disease (GvHD) of all grades was analyzed by Mantel-Haenszel Chi-Square Test. 
The overall survival rate was estimated by the method of Kaplan-Meier. The cumulative incidence 
was  estimated  for  the  time  to  first  AdV  positivity  in  PB  and  time  to  onset  of  AdV  disease. 
Depending on the subgroup analyzed, the intervals start at BMT, at first AdV positivity in PB, or 
at the time of AdV disease onset, respectively (Fig.1). For the comparison of patients who tested 
AdV positive in PB with patients who tested negative in PB, the interval for the latter group starts 
at the median time to AdV positivity (i.e. day +16), to account for the time-dependent nature of 
AdV positivity in PB (Fig.1c). The impact of CMV positivity, AdV positivity, and AdV disease 
on survival was studied by including the respective variables as time-dependent co-variates in a 
Cox regression model. The impact of CMV positivity on the time to AdV positivity in PB was 
analyzed in the same fashion. Relative hazard rates (relative risk) are indicated in addition to p-
values. All indicated p-values are two-sided. P values ￿0.05 were considered significant, p values 
￿0.01 highly significant.
Definitions 
Localized and disseminated adenovirus infection, definite and probable adenovirus disease were 
defined as described 
11; 28, with minor modifications reflecting the use of PCR detection assays: 
Patients with reproducibly positive adenovirus PCR screening assays in specimens derived from 
any site or positive tests from sources related to their clinical signs and symptoms were considered 
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to have adenovirus infection. Disseminated (invasive) infection was defined as the presence of 
positive tests from two or more organ systems and/or positive tests from peripheral blood. 
Definite disease was defined as the presence of typical adenovirus nuclear inclusions on routine 
histopathology, a positive culture from tissue (except from the  gastrointestinal tract), or both. 
Probable adenovirus disease was defined as the presence of two or more positive PCR assays in 
samples from peripheral blood or from more than two different body sites, in association with 
compatible  symptoms,  without  other  identifiable  causes.  All  patients  with  fever,  unexplained 
symptoms, or laboratory test abnormalities were carefully tested for infections and for GvHD.
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Results
Incidence  and  spectrum  of  adenovirus  infections  in  children  after  allogeneic  stem  cell 
transplantation
Patients who tested AdV positive are summarized in Tab.3. Thirty six patients (27%) showed 
positive results in samples derived from at least one site. Among the AdV positive patients, twenty 
five (69%) had detectable virus at one or two sites, most commonly in stool and/or throat samples, 
but never tested positive in peripheral blood (PB) (Tab.3, upper panel). In these patients, AdV 
positivity has appeared at a median of 18 days post-transplant (range –7/> +100). Patients who 
tested AdV positive at more than two different sites also showed presence of the virus in PB. 
Adenoviruses were detected in PB samples of eleven children, i.e. 31% of the AdV positive cases, 
and 8% of all patients (Fig. 1a; Tab.3, bottom panel). First appearance of adenoviral DNA in PB 
specimens has been observed at a median of 16 days post-transplant (range –7/> +100).
In our series, adenoviruses of all but one species were detected: groups A, B, C, D, and F were 
represented, but no sample was positive for species E, the smallest subgroup including only one 
serotype (No 4). The most prevalent AdV species in the cohort investigated was group C (78% of 
all positive cases), while other types were observed less frequently: (A:8%; B:8%; D:8%, F:8%). 
Four patients were positive for two different AdV species: in two instances, the species C+B were 
present, two other patients displayed the species A+B, and D+F, respectively. Among patients 
who tested positive in PB, nine (82%) displayed species C, and two (18%) species A.
Risk factors for AdV infection 
T-cell depletion in vivo by  ATG combined with T-cell depletion ex vivo by CD34+ positive 
selection was associated with a significantly increased incidence of AdV infection (p=0.014). T-
cell depletion by ATG alone showed no significant association (p=0.493). Children who were 
For personal use only. on November 3, 2014.  by guest    www.bloodjournal.org From 10
transplanted from matched sibling donors (MSD) had a significantly lower occurrence of AdV 
infection in comparison to the cohort of patients with matched unrelated (MUD) and mismatched 
family (MMFD) donors (p=0.014).
No statistically significant correlation with AdV detection has been found for other parameters 
incl uding the presence of graft versus host disease (GvHD), regardless of the grade (p=0.725), and 
for the underlying disease (non-malignant versus malignant)  (p=0.314).
Association of AdV detection with presence of other viruses 
Of the viruses tested in addition to AdV including CMV, EBV, HHV6, and HHV7, only CMV 
was significantly correlated with detection of AdV in PB. Within the group of AdV PB positive 
patients, 8/11 (73%) had detectable CMV in PB versus 33/96 (34%) in AdV negative patients 
(p=0.020). By contrast, the difference in the detection of CMV in PB between AdV negative cases 
and patients who tested AdV positive at sites other than PB, 33/96 (34%) versus 10/25 (40%), was 
not significant (p=0.601).
In the patients with positive PB tests for both AdV and CMV during the time of observation, all 
but one revealed CMV positivity before the first positive AdV test (Table 3). However, in contrast 
to  the  dynamics  of  AdV  load  observed  in  most  of  these  patients  (see  below),  there  was  no 
evidence of increasing CMV levels in PB. Cox regression analysis revealed that patients who 
tested CMV positive in PB had a 4.4-fold increased risk of invasive AdV infection. However, 
detection of CMV in PB per se, in absence of expanding viral load, was not a significant factor for 
survival in the patients studied (relative risk: 1.3). Hence, despite a significant association with 
later occurrence invasive AdV infection, CMV was not an independent co-variable with regard to 
transplant related mortality (TRM).
Adenovirus infection and transplant related mortality 
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In  children  with  AdV  detectable  at  sites  other  than  PB,  the  only  signs  of  adenoviral  disease 
included enteritis in seven patients with AdV positivity in stool specimens, and generalized rash in 
one patient with AdV positive skin biopsy (Tab.3). By contrast, eight of eleven patients who had 
detectable AdV in PB had clinical evidence of disseminated adenoviral disease (Fig. 1b; Tab.3). 
In the group of AdV negative patients, 28 children (29%) died during the observation period. In 
eight instances (8%), the fatal outcome was attributable to disease relapse, and in 20 cases (21%) 
to TRM. In the cohort of adenovirus positive patients who had no detectable AdV in PB (Tab.3, 
pts 1-25), eight (32%) died. One patient (4%) died from the underlying disease, and seven (28%) 
from TRM (i.e. organ toxicity n=3, or infectious complications including CMV-pneumonia n=1, 
legionella n=1, and invasive aspergillosis n=2). The difference in TRM-related deaths between the 
two cohorts, 21% vs 28%, was not statistically significant (relative risk:1.2; p=0.706). In the group 
of patients who were AdV positive in PB (Tab.3, pts 26-36), ten (91%) died. One patient (9%) 
died from relapse, and nine (82%) from TRM. The association of AdV positivity in PB with TRM 
was highly significant (relative risk: 5.8; p<0.001)(Fig. 1c). One of these patients died from CMV 
pneumonia over three months after transient AdV positivity in PB, and eight children developed 
disseminated AdV disease with multiorgan (hepatic, pulmonary, renal) failure. The correlation 
between onset of AdV-related disease and mortality was highly significant (relative risk: 31.4; 
p<0.001). Adenoviral DNA was detected in PB at a median of 29 days before death (range 7 to 
112 days). The AdV types observed in PB of these patients belonged either to species C (n=6) or 
A (n=2). 
Quantification of virus load in patients with invasive AdV infection
In patients who tested AdV positive at any site, virus load was monitored at three- to four-day 
intervals. The virus load was usually low in patients presenting with AdV positivity at sites other 
than PB (<2x10
4 virus copies per gram of tissue, e.g. stool, or per milliliter of liquid, e.g.urine), 
and there was mostly no evidence of rising virus copy numbers during the observation period. 
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Only three patients (Tab.3; No 19, 35, and 36) showed dramatically increasing AdV levels in stool 
samples, reaching copy numbers of >10
8/g. During this period, one of the patients (No 19) had 
hemorrhagic  diarrhea,  which  was  treated  with  cidofovir,  and  resolved  together  with  prompt 
reduction of AdV load in stool. Two other patients (No 35, 36) later showed AdV positivity in PB 
with rapidly rising virus load, and died shortly thereafter. 
Among patients who tested AdV positive in PB (Tab.3, bottom panel), three showed only transient 
positivity  with  virus  copy  numbers  ranging  between  2x10
2  and  2x10
3  per  ml  PB  or  per  10
6
leukocytes, without any dynamics indicative of virus proliferation. None of these patients had 
evidence of adenoviral disease during the observation period; one is alive and well 30 months 
post-transplant, one died from disease relapse, and one died from CMV pneumonia more than 
three months after AdV had become negative in PB (Tab.3, No 32, 29, and 27, respectively). All 
other  patients  who  had  detectable  AdV  in  PB  developed  disseminated  disease  (Fig.  1b).  The 
maximum AdV load in PB detected in these patients prior to the onset of disease varied over more 
than four logs: three patients had very high maximum levels >10
7 (Tab.3; No 26, 28, 34), two had 
intermediate levels of 10
5 and 5x10
6, respectively (Tab.3; No 35, 36), but in three patients the 
maximum virus copy numbers detected were low, ranging from 1-9x10
3 (Tab.3; No 30, 31,33). 
With the exception of two children who died very shortly after first detection of the virus in PB 
(Tab.3; No 30, 31), the virus load in PB could be monitored by quantitative PCR analysis during 
the  course  of  infection.  In  these  patients  (Tab.3;  No  26,  28,  33-36),  the  kinetics  of  AdV 
proliferation revealed a tenfold increase in virus load at a median of 21 days (range 6 to 37 days) 
prior to the onset of clinical symptoms, and 26 days (range 12-118 days) prior to fatal outcome. 
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Discussion
In  the  current  study,  pediatric  patients  undergoing  allogeneic  SCT  were  investigated  for 
adenovirus infections by a pan-adenoviral PCR-assay system. The observation of AdV infections 
in 27% of the children investigated is rather high in comparison with earlier retrospective studies 
11;  13;  20;  24;  29-31. In the patients presented, detection of adenovirus at more than two sites was 
always associated with presence of the virus in peripheral blood (PB), indicating the presence of 
invasive virus infection 
11; 21; 32. In these patients, AdV was first detected at a median of 16 days 
post-transplant. In children with non-invasive AdV infections, with detectable virus at one or two 
sites not including PB, the virus was detected at a median of 18 days post SCT. However, the time 
range of first AdV detection was rather large in both groups (Tab.3), as reported previously 
11; 29; 
31. 
In  the  clinical  setting,  species  identification  of  an  AdV  isolate  has  been  reported  to  be  as 
informative as the analysis of individual serotypes 
6; 25. Specific targeting of AdV DNA sequences 
by  PCR  is  hampered  by  major  genetic  differences  between  the  six  species,  with  an  overall 
sequence homology of less than 25% 
8; 33; 34. Most of the published PCR assays for AdV detection 
are based on amplification of fragments derived from the hexon gene, the most highly conserved 
gene  in  the  AdV  genome 
17;  34-37.  Comparative  analysis  of  the  currently  available  sequence 
information on the hexon gene from different types of adenovirus revealed a nucleotide homology 
of about 50% (NCBI Database). This observation explains the apparent difficulty in establishing 
diagnostic assays that permit detection of the entire spectrum of human adenoviruses. Indeed, 
careful sequence analysis indicated that some of the published PCR tests targeting the hexon gene 
that were supposed to cover all AdV types are not likely to meet the expectations 
4; 38-43. 
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For the purpose of this study, we have therefore established species-specific real-time quantitative 
PCR  assays  covering  the  entire  spectrum  of  known  human  AdV  types.  Fatal  infections  were 
observed  in  patients  infected  with  the  AdV  species  A  and  C.  Other  studies  in  patients  after 
allogeneic SCT, after chemotherapy of malignant disorders or after organ transplantation have 
reported fatal outcome for infections with other AdV types including also the species B, D, E, and 
F 
2; 3; 8; 11; 21; 24; 40; 44. In our series, species C was by far the most prevalent type of adenovirus, and 
most  of  the  fatal  infections  were  associated  with  this  AdV  subgroup.  However,  the  reported 
prevalence of individual AdV types associated with severe infections at various transplant centers 
was quite heterogeneous 
2; 3; 8; 11; 21; 24; 40; 44. The data available to date indicate that adenoviruses of 
any species may cause life-threatening infections in allografted patients. In view of the fact that 
there is no clear evidence against the association of individual AdV types with severe infections, 
the screening methods employed in immunocompromised patients should be required to permit 
sensitive  detection of all adenoviral serotypes.
Our  experience  indicating  that  detection  of  adenovirus  at  multiple  (i.e.  more  than  two)  sites 
reflects  presence  of  invasive  infection,  is  in  concert  with  other  reports 
21;31;32.  In  our  series, 
however, 73% of the patients with AdV detectable in PB, but none of the patients with AdV 
detectable at sites other than PB, developed fatal disseminated AdV disease. First detection of the 
virus in PB preceded fatal outcome of the infection by a median of 29 days. In agreement with a 
recent retrospective pilot study
13, our results demonstrate that detection of AdV in PB is highly 
predictive for TRM (p<0.001). 
Some of the patients who developed disseminated disease had very high levels of AdV copies in 
PB (>10
7/ml or per 10
6 cells), while others had relatively low peak levels, between 10
3 and 10
4. 
Regardless of the maximum AdV levels reached, quantitative monitoring of virus load by real-
time PCR usually revealed rising virus copy numbers before the onset of clinical symptoms. It 
For personal use only. on November 3, 2014.  by guest    www.bloodjournal.org From 15
should  be  noted  that  the  documentation  of  virus  proliferation  virtually  eliminates  a  problem 
inherent  in  PCR  diagnosis,  the  occurrence  of  false  positive  PCR  tests  due  to  inadvertent 
contamination  with  extraneous  nucleic  acids.  Moreover,  the  assessment  of  virus  proliferation 
kinetics permits clear distinction between latent and active adenovirus infection. We have shown 
previously for quantitative PCR assays that a tenfold increase of the respective target copy number 
is  well  beyond  the  intrinsic  variability  of  the  method,  and  provides  reliable  evidence  of  an 
expanding process 
45. Tenfold increase in virus load preceded clinical signs of adenovirus disease 
by  a  median  of  three  weeks.  These  observations  indicate  that  monitoring  of  adenovirus 
proliferation kinetics is more informative than the assessment of absolute virus load at a given 
time point. Our results therefore suggest that repeated detection of AdV in peripheral blood, and 
documentation of rising virus copy numbers may provide the most reliable approach to diagnosis 
of  invasive  infection  and  prediction  of  adenovirus  disease.  It  is  necessary  to  keep  in  mind, 
however, that the options for effective therapy directed against adenoviral disease are still limited 
12;  30;  32;  46-50,  and  that  delayed  onset  of  treatment  has  been  associated  with  a  greater  risk  of 
treatment  failure 
49.  In  view  of  the  highly  significant  association  of  adenovirus  detection  in 
peripheral blood with the risk of fatal virus disease, a positive PCR test in PB should prompt the 
initiation  of  preemptive  antiviral  treatment.  The  availability  of  firm  evidence  for  actively
proliferating, invasive adenoviral infection, as revealed by rising virus numbers in PB, will gain 
clinical relevance when more effective anti-adenoviral treatment becomes available. Currently, the 
main  use  of  quantitative  monitoring  of  adenoviral  load  is  the  assessment  of  the  efficacy  of 
treatment. The surveillance of patients after hematopoietic stem cell transplantation by molecular 
techniques that permit rapid and sensitive detection of the entire spectrum of human adenoviruses 
can be expected to contribute to an improvement of clinical outcome in patients with invasive 
adenoviral infections. 
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Table 1
Patient characteristics, transplant modalities and acute GvHD
N = 132
Observation time: median 23 months  (range: 2-71)
Age at SCT: median 8 years  (range: 0.1-20)
Diagnosis: Acute leukemia  n=63
Chronic leukemia/Myelodysplasia/Solid tumor  n=23
Severe combined immunodeficiency  n=  8
Inborn errors/Severe aplastic anemia n=38
Conditioning: Chemoconditioning    n=  80
Irradiation (TBI/TLI)-containing conditioning    n=  52
Additional anti-thymocyte globulin  (ATG)  n=103
Donor: HLA-matched sibling donor    n=  35
HLA-matched unrelated donor    n=  68
HLA-mismatched family donor    n=  29
Graft: Bone marrow without CD34+ positive selection  n=  62
Peripheral blood stem cells without CD34+ positive selection  n=  12
Peripheral blood stem cells with CD34+ positive selection n=  58
Acute GvHD: All patients (pts) (n=132): GvHD, any grade n=  72
GvHD, grade III-IV n=  27
AdV negative pts (n=96): GvHD, any grade n=  51
GvHD, grade III-IV n=  18
AdV positive pts at any site (n=36) GvHD, any grade n=  21
GvHD, grade III-IV n=    9
AdV positive pts in PB (n=11) GvHD, any grade n=    5
GvHD, grade III-IV n=    3
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Table 2
Primers and probes for species-specific adenovirus detection by real-time PCR
Acronym/
Virus type
Target
Amplicon 
length
Oligonucleotide sequence (5´-3´)
Forward ￿ ￿￿￿ Probe￿ ￿￿￿ Reverse
Conc.
(nM)
Nucleotide 
position
GenBank 
Acc. No.
AdV A Hexon gene 135 bp GGK CTG GTG CAA TTC GCC 300 17818 - 17835 X73487
CCA CGG ACA CCT ACT TCA CCC TGG G 200 17840 - 17864
CAC GGG CAC AAA ACG CA 300 17936 - 17952
AdV B  Hexon gene 138 bp CGC CGG ACA GGA TGC TT 900 45 - 61 X76549
(B + E) AGT CCG GGT CTG GTG CAG TTC GCC  200 73 - 96
CTA CGG TCG GTG GTC AC 900 166 - 182
AdV C Hexon gene 138 bp ACC TGG GCC AAA ACC TTC TC 300 2884 – 2903 J01966
AAC TCC GCC CAC GCG CTA GA 200 2910 – 2929
CGT CCA TGG GAT CCA CCT C 900 2940 - 2958
AdV D VA RNA gene 143 bp AAA AAC GAA AGC GGT TGA GC 300 2 – 21 U10675
CCA ATA CCA CGT TAG TCG CGG CT 200 104 – 126
CGG GTC GAG ACG GGA GT 50 128 - 144
AdV E Hexon gene 75 bp CAA CAC CTA CTC GTA CAA AGT GCG 900 225 – 248 X84646
CGC CCA CGG CCA GCG TGT  200 251 – 268
TAG GTG CTG GCC ATG TCC A 300 281 - 299
AdV F Hexon gene 128 bp GCA GGA CGC CTC GGA GTA 300 268 – 285 D13781
TAC TTC AGC CTG GGG AAC AAG TTC AGA AA 200 329 – 357
TGT CTG TGG TTA CAT CGT GGG T 900 374 - 395
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Patient AgeDiagnosis Donor Source T-cell  aGvHD during  AdV- Site of detection Day of CMV Day of AdV AdV Outcome Day of death / Cause 
No. depletion AdV infection species detection in PB detection  disease post BMT
/ Grade pre/post BMT pre/post BMT
1 9 WG MSD BM no no D stool +56 +7 no a/w
2 3 AML  MUD PBSC 1+2 no C stool -13   0 no a/w
3 20 ALL MUD BM 1 no F stool, organ biopsy (postmortem) n.d. +59 no died +101 / CMV
4 1 HLH MMFD PBSC 1+2 n.e. F stool, throat -10 -7  enteritis died +2 / HLH
5 8 ALL MMFD PBSC 1+2 no C stool + 1 > +100 enteritis a/w
6 3 ALL MUD PBSC 1+2 no A stool +17 > +100 enteritis died +131 / toxicity
7 8 ALL MUD BM 1 no
+
C stool +12 +90 no a/w
8 3 FHL MUD PBSC 1+2 no C+B stool, throat (C) / stool (B) -5 -7 (C) / > +100 (B) no died +153 / aspergillus
9 5 FA MMFD PBSC 1+2 no C stool n.d. +49 enteritis died +70 / toxicity
10 2 FHL MMFD PBSC 1+2 no C throat n.d. > +100 no a/w
11 10 ALL MMFD PBSC 1+2 no C stool n.d. +91 no died +120 / legionella
12 10 CML MSD BM no no C skin n.d. > +100 rash a/w
13 7 SAA MFD PBSC 1+2 no C throat n.d. > +100 no a/w
14 3 AML  MUD PBSC 1 no C organ biopsy (postmortem) n.d. +39 no died +39 / toxicity
15 16 SAA MMFD PBSC 1+2 n.e. C throat n.d. +10 no died +74 / aspergillus
16 4 XLP MUD PBSC 1+2 no C stool n.d. +8 no a/w
17 11 AML  MSD BM no no D stool +52 +10 no a/w
18* 1 MPS I MUD PBSC 1+2 yes/3 C stool +6 +53 enteritis a/w
19* 1 MPS I MUD PBSC 1+2 yes/3 C stool n.d. +23 enteritis a/w
20 7 MDS MSD BM no no C stool -12 -7 no a/w
21 0 SCID MMFD PBSC 1+2 no C stool n.d. +18 enteritis died +170 /SID
22 9 ALL MUD PBSC 1 no C stool n.d. -7 no a/w
23 1 HLH MUD PBSC 1+2 no C stool n.d. -7 no a/w
24 8 AML  MUD BM 1 no D+F stool n.d. -7 (D)/+19 (F) no a/w
25 1 SGD MUD BM 1 no C stool n.d. -7 no a/w
26* 5 ALL MMFD PBSC 1+2 no C PB +4 +16 disseminated died +69 / AdV
27 0 JMML MUD BM 1 no C PB, stool, throat -11 +18[PB: +20] no died +424 / CMV 
28 5 ALL MMFD PBSC 1+2 no
+
C PB, stool, organ biopsy (postmortem) > +100 [+139] > +100 [PB:+150] disseminated died +198 / AdV
29 3 AML  MMFD PBSC 1+2 no C PB, stool, urine +41 -7 [PB:+13]  no died +302 / relapse
30 9 FA MUD PBSC 1+2 no C PB, stool, urine, throat +38 +72 disseminated died +79 / AdV
31* 9 CML MUD PBSC 1+2 no C PB, organ biopsy (postmortem) -43 -7  disseminated died + 8 / AdV
32 2 JMML MUD BM 1 yes/2 C PB n.d. +13 no a/w
33 12 AML  MUD PBSC 1 no C PB, stool, throat, urine,  +14 +36 disseminated died +64 / AdV
organ biopsy (postmortem)
34 3 AML  MUD PBSC 1+2 no A PB, throat, liver -10 -7   disseminated died +24 / AdV
35 8 ALL MMFD PBSC 1+2 no A+B PB, stool, throat, urine, CSF (A) / stool (B) n.d. +11 (A)/-7 (B) disseminated died +31 / AdV
36* 2 MPS I MUD PBSC 1+2 yes/4 B+C PB, stool, throat, urine, CSF, eye (C)/ stool (B) n.d. -7(C) [PB:+26]/> +100 (B) disseminated died +151 / AdV
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Table 3. Characteristics of adenovirus-positive patients
Upper panel (No 1-25): patients who tested RQ-PCR positive at one or two sites other than 
peripheral blood. Bottom panel (No 26-36): patients who tested RQ-PCR positive at sites 
including peripheral blood. Patients who had undergone a prior SCT (No 18, 19, 26, 31, 36) 
are marked by an asterisk (column Patient No). In the column aGvHD , the highest grade of 
acute graft versus host disease observed during the time of AdV infection is indicated. (For 
overall  incidence  of  acute  GvHD  during  the  post-transplant  period,  see  Table  1).  Two 
patients  (marked  by 
+)  had  chronic  GvHD  during  the  course  of  AdV  infection.  In  both 
instances (No 7, 28) the GvHD was graded as extensive. In the column Day of AdV detection, 
the appearance of AdV in PB is indicated in brackets, if the virus was first detected at a site 
other than PB. In the column Day of CMV detection, patient No 31 is indicated as CMV 
positive on day –43. The availability of CMV data at this unusual time point is attributable to 
the fact that the patient had undergone his first SCT over 3 months earlier. In patients who 
had both AdV and CMV detectable in PB (No 26-31, 33, 34), the median time point of first 
PCR positivity was day +9 (range –43 to +139) for CMV and +14.5 (range –7 to +150) for 
AdV. In one instance (No 31), AdV detection in PB preceded that of CMV by 28 days, but in 
the remaining cases detection of CMV preceded first AdV positivity in PB by 3 to 36 days 
(median 17 days). None of the patients who tested CMV positive prior to transplantation had 
evidence of active infection, as revealed by RQ-PCR monitoring. Two patients (No 31 and 
34) had AdV detectable in PB at the commencement of conditioning, but the transplantation 
could not be postponed due to the presence of leukemia in progression. In all other patients 
with AdV infection prior to transplantation, the virus was detectable in stool only.
Abbreviations:  BMT=bone  marrow  transplantation;  WG=  Wegener´s  granulomatosis, 
AML=acute myeloid leukemia; ALL=acute lymphoblastic leukemia; HLH=hemophagocytic 
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lymphohistiocytosis;  FHL=familial  hemophagocytic  lymphohistiocytosis;  FA=Fanconi 
anemia;  CML=chronic  myeloid  leukemia;  SAA=severe  aplastic  anemia;  XLP=X-linked 
lymphoproliferative  diseae;  MPS  1=  mucopolysaccharidosis  type  1;  JMML=juvenile 
myelomonocytic  leukemia;  SCID=severe  combined  immunodeficiency;  SGD=chronic
granulomatous  disease;  MSD=matched  sibling  donor;  MUD=marrow  unrelated  donor; 
MMFD=mismatched  family  donor;  BM=bone  marrow;  PBCS=peripheral  stem  cell 
transplantation;  T-cell  depletion:  1=anti-thymocyte  globulin  (ATG);  2=CD34+  positive 
selection;  CSF=cerebrospinal  fluid;  a/w=alive  and  well;  SID=sudden  infant  death; 
CMV=cytomegalovirus; AdV=adenovirus; n.d.=not detected, n.e.=not evaluable.
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Figure 1. Incidence of invasive adenovirus infection, disseminated disease and 
overall survival
Panel a.  Probability of invasive AdV infection and disease
In the cohort of patients investigated, the one-year cumulative incidence of invasive AdV infection 
post SCT (dashed curve), documented by virus detection in peripheral blood, was 8% (+8%), that 
of AdV-associated disease (solid curve) 6% (+6%). 
Panel b. Probability of disease after AdV detection in PB
The cumulative incidence of disease was 73% (+10%) within 60 days after the first AdV positive 
PCR test in PB.
Panel c. Probability of survival in patients with AdV positive/negative PCR tests 
The black (bottom) curve indicates the overall survival in patients with AdV positivity in PB. The 
one-year probability of survival (pSU) in this cohort was 18% (+9%). The two upper, nearly 
identical curves illustrate the overall survival in patients who tested AdV negative in PB, but 
positive at one or two other sites (dashed grey curve; one-year pSU of 64% (+10 %).), and in AdV 
negative patients (solid grey curve; one-year pSU of 67% (+5 %). The difference between patients 
positive for AdV in PB and the other two cohorts illustrated is highly significant (p<0.001). By 
contrast, there was no statistically significant difference in pSU between AdV negative patients 
and patients who tested AdV positive at sites other than PB (p=0.706). 
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